<DOC>
	<DOCNO>NCT02661711</DOCNO>
	<brief_summary>The purpose study assess safety efficacy intravitreal injection Aflibercept ( Eylea ) treat Cystoid Macula Oedema ( CMO ) patient underlie Retinitis Pigmentosa ( RP ) .</brief_summary>
	<brief_title>Aflibercept Macular Oedema With Underlying Retinitis Pigmentosa ( AMOUR ) Study</brief_title>
	<detailed_description>This 17 month phase II therapeutic exploratory trial Cystoid Macular Oedema ( CMO ) underlie Retinitis Pigmentosa ( RP ) . The study design prospective , open-label , interventional non-randomised trial . All patient enrol study receive intravitreal injection Aflibercept ( Eylea ) . There 9 month recruitment window patient participation 12 month ; 30 patient age 16 year old present Medical Retina Genetics clinic Moorfields Eye Hospital Cystoid Macula Oedema ( CMO ) underlie Retinitis Pigmentosa ( RP ) approach study team discuss participation AMOUR study give patient information leaflet . If patient decide participate study invite NIHR Moorfields Clinical Research Facility baseline screen write informed consent give patient various assessment perform confirm eligibility . Patients enrol study receive intravitreal injection 2mg 40mg/ml Aflibercept ( Eylea ) solution study eye . In first three month , patient receive load dose Aflibercept ( Eylea ) one injection every four week . After first three month , treatment frequency follow treat extend protocol 12 month date study enrolment . Extension 4 weekly 6,8,10 12 week follow occur reduction macula fluid compare previous visit . Patients receive minimum 5 injection deem non-responders treatment . Imaging assessment optical coherence tomography imaging , microperimetry visual acuity use assess response treatment .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>CMO association RP &gt; 16 year age Unilateral Bilateral CMO ( bad eye treat defined eye great central macular thickness ( CMT ) OCT ) No previous oral treatment CMO last 3 month No previous peribulbar intravitreal treatment CMO study eye last 3 month No previous topical treatment CMO study eye last 1 month Central visual impairment view Principal Investigator due CMO BCVA well 3/60 Insufficient patient cooperation medium clarity allow adequate fundus imaging . Evidence visually significant vitreoretinal traction epiretinal membrane OCT Principal Investigator 's opinion highly likely significantly limit efficacy intravitreal therapy . History cataract surgery within prior 3 month cataract surgery anticipate within 6 month start study . Any antiVEGF treatment study eye within 3 month . History YAG capsulotomy perform within 3 month . Uncontrolled Intraocular pressure ( IOP ) &gt; = 24 mmHg ocular hypertension ( topical IOP lower medication ) Advanced glaucoma ( opinion glaucoma specialist ) . Patients active suspect ocular periocular infection Patients active severe intraocular inflammation . Patients new , untreated retinal tear detachment Patients stage 3 4 macular hole Thromboembolic event ( MI/CVA/Unstable Angina ) within 6 month . Pregnancy family plan within 15 month Females breast feed Known allergy hypersensitivity antiVEGF product Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 12 week treatment discontinuation . The MHRA advise double contraception . Females childbearing potential must negative pregnancy test within 7 day prior registered trial treatment . Note : Subjects consider child bear potential surgically sterile ( i.e . undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Macular Oedema Retinitis Pigmentosa</keyword>
</DOC>